Isofol Medical AB (publ) (STO:ISOFOL)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.7630
-0.1120 (-12.80%)
Feb 26, 2026, 5:29 PM CET
Market Cap214.48M -26.7%
Revenue (ttm)n/a
Net Income-54.17M
EPS-0.25
Shares Out281.11M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,210,188
Average Volume2,881,187
Open0.8600
Previous Close0.8750
Day's Range0.6800 - 0.8600
52-Week Range0.5515 - 2.4400
Beta0.83
RSI75.67
Earnings DateFeb 18, 2026

About Isofol Medical AB

Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol ISOFOL
Full Company Profile

Financial Performance

Financial Statements